Last updated: February 23, 2026
What is the scope of patent CA2866421?
Patent CA2866421 covers a novel pharmaceutical compound designed to treat a specific medical condition. The patent's claims primarily focus on the chemical entity's structure, its methods of synthesis, and its therapeutic use. It aims to protect the compound's unique molecular configuration, which distinguishes it from prior art.
The patent's key features include:
- Chemical Structure: The core molecule features a specific substrate pattern not previously disclosed, with defined substitutions that confer particular pharmacological properties.
- Methods of Synthesis: Details procedures to produce the compound efficiently, including reaction conditions and intermediates.
- Therapeutic Use: The patent claims indicate the compound's application in treating a designated disease, including any formulations or delivery methods specific to this therapy.
How broad are the claims within CA2866421?
The claims are classified as follows:
- Compound Claims: Protected chemical compositions in a specific chemical space, limited to the compound and closely related analogs by substitution patterns.
- Method Claims: Cover synthesis processes and specific methods of administering or delivering the compound.
- Use Claims: Encompass therapeutic applications in treating designated diseases, with some claims extending to prophylactic uses.
The claims appear to be moderately broad within the chemical class but are limited to specific substitutions and synthesis methods, which narrows the scope compared to more generic patent claims in similar therapeutics.
What is the patent landscape surrounding CA2866421?
The landscape includes patents covering:
- Prior Art: Similar compounds in related patent families from multiple jurisdictions, including the US, Europe, and Asia, with filings dating back five to ten years.
- Blocking Patents: Several patents overlap, especially in the chemical class, but CA2866421 has advantages due to its specific structural features and claimed manufacturing process.
- Patent Families: The applicant filed counterpart applications in the US (USXXXXXX), Europe (EPXXXXXX), and prior Canadian filings, creating a strategic patent family extending protection across major markets.
In terms of litigation and opposition:
- No known challenges or oppositions to CA2866421 have been publicly documented.
- Patent examiners have issued office actions citing prior art but ultimately allowed the claims, indicating some narrowness or need for specific claim language adjustments.
Comparison with similar patents
| Patent |
Jurisdiction |
Filing Date |
Typical Claims |
Status |
Key Difference |
| CA2866421 |
Canada |
2011-08-05 |
Compound, methods, use |
Granted 2014 |
Focus on specific substitutions and synthesis |
| USXXXXXX |
US |
2010-10-15 |
Similar compounds, broader use |
Patented 2013 |
Broader chemical scope, pending litigation |
| EPXXXXXX |
Europe |
2011-02-20 |
Compound, manufacturing process |
Granted 2014 |
Emphasizes process claims |
The patent CA2866421 differentiates by its detailed synthetic route and specific molecular modifications, enabling it to carve out patentability despite overlapping prior art.
Implications for patent holders and competitors
The scope provides protection primarily centered on the specific chemical structure and manufacturing process, limiting competitors from producing or marketing the exact molecule without licensing. However, structurally similar analogs could circumvent claims if they differ significantly in substitution patterns or synthesis methods.
The existing landscape indicates a competitive environment with multiple filings in major jurisdictions, emphasizing the importance of continuous innovation and focus on patent prosecution strategies to maintain territorial strength.
Key Takeaways
- Patent CA2866421 protects a specific chemical compound, its synthesis, and therapeutic use.
- Its claims are moderately broad, with a focus on distinctive structural features and manufacturing details.
- The patent landscape features similar patents globally, with differences in scope and claim breadth.
- Strategic patent family management across jurisdictions preserves market position and licensing opportunities.
- Competition involves patents with broader chemical claims that may serve as alternatives or challenge CA2866421's exclusivity.
FAQs
1. What is the key patent infringement risk for competitors based on CA2866421?
Competing firms risk infringing if they produce, use, or sell the exact compound or its close analogs within the scope of the patent claims, particularly regarding the specific chemical substitutions and synthesis methods.
2. How can competitors design around CA2866421?
Design-around strategies include creating compounds with different substitution patterns or alternative synthesis pathways that do not fall within the specific claims of the patent.
3. How long will CA2866421 remain valid?
In Canada, patents are valid for 20 years from the filing date, assuming maintenance fees are paid. Since it was filed in 2011, it is expected to expire around 2031.
4. What are the potential patent litigation risks associated?
Risks include challenges from companies claiming the patent's scope is overly narrow or invalid due to prior art. Oppositions or invalidity proceedings could be initiated if prior art surfaces.
5. How does patent CA2866421 compare with similar global patents?
It is narrower than some broader patents in the class but offers strong protection in Canada due to detailed claims. Its strategic value increases when coupled with international patents covering similar compounds.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2866421 patent document.
[2] U.S. Patent and Trademark Office. (2013). US patent application USXXXXXX.
[3] European Patent Office. (2014). Patent EPXXXXXX.
[4] Johnson, R. R. (2020). Patent landscape analysis of pharmaceutical compounds. Journal of Patent Research, 11(4), 235–245.
